Auto-immune diseases are characterized by an inappropriate inflammatory response against tissues in the body. These diseases, of which rheumatoid arthritis (RA) is the most well-known, represent a major health care burden. Pro-inflammatory cytokines such as TNF-α, IL-6 and IL-1β are central in the pathogenesis of RA and many other auto-immune diseases. Biologics that antagonize inflammatory cytokines or their receptors, e.g. anti-TNF-α, soluble TNF-α-receptor, anti-IL-6 receptor, and IL-1 receptor antagonist, are very effective treatments. However, they are very expensive and can have serious side effects. Furthermore, the consequences of RA are currently completely beyond the patients' sphere of influence. Therefore, innovative therapies aimed at limiting inflammation in RA patients are warranted.